Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 11/20 | 0.52 |
| ▸ | MMP1 | P03956 | 5/20 | 0.52 |
| ▸ | MMP7 | P09237 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 8/20 | 0.49 |
| ▸ | CA1 | P00915 | 5/20 | 0.47 |
| ▸ | CA2 | P00918 | 5/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9289897 | 0.91 | MMP3 (0.58) | MMP3MMP1MMP7MMP2 | |
| SCHEMBL7763165 | 0.89 | MMP3 (0.56) | MMP3MMP1MMP7MMP2 | |
| SCHEMBL7763668 | 0.88 | MMP3 (0.54) | MMP3MMP1MMP7MMP2 | |
| SCHEMBL7764977 | 0.87 | MMP3 (0.59) | MMP3MMP1MMP7MMP2 | |
| SCHEMBL7758535 | 0.87 | MMP3 (0.59) | MMP3MMP1MMP7MMP2 | |
| SCHEMBL7763782 | 0.86 | MMP3 (0.51) | MMP3MMP1MMP7MMP2 | |
| SCHEMBL7763701 | 0.82 | MMP3 (0.50) | MMP3MMP1MMP7MMP2 | |
| SCHEMBL7758445 | 0.82 | MMP2 (0.52) | MMP3MMP1MMP7MMP2 | |
| SCHEMBL7763176 | 0.82 | MMP3 (0.53) | MMP3MMP1MMP7MMP2 | |
| SCHEMBL7763812 | 0.81 | MMP3 (0.54) | MMP3MMP1MMP7MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |